The interaction of CD28 with one of the B7 molecules (CD80 and CD86) on professional antigenpresenting cells (APC) is generally considered as the most important co-stimulatory signal for T cell activation. APC in a resting condition express either no or only low levels of B7 molecules. These are up-regulated as a result of interactions with activated T cells, thus suggesting that B7-CD28 interaction is not required at initiation of T cell activation. To study this issue, we blocked B7-CD28 interaction at various time points after in vitro stimulation of peripheral blood T cells with allogeneic monocytes, Epstein-Barr virus-transformed B cells or soluble antigens. We observed that T cell proliferation and IL-2 production were inhibited by B7-blocking agents (CTLA-4-Ig or anti-B7 mAb) almost to the same degree when added either at initiation of culture or 24 h later. B7-blocking agents still resulted in significant inhibition of allogeneic T cell activation when added after 48 h. Furthermore, when CTLA-4-Ig was added at the start of an allogeneic T cell stimulation, addition of anti-CD28 mAb after 24 h of culture nearly fully restored T cell proliferation to control levels. Finally, we demonstrate that delayed addition of B7-blocking agents together with cyclosporin A 1 day after the onset of culture of T cells with allogeneic B cells is highly efficient to induce anergy as evaluated by lack of proliferation, cytotoxic T lymphocyte reactivity and IFN-γ or IL-5 production upon alloantigen rechallenge. Taken together, our data can explain why B7 expression on APC is not required at the time of initial APC-T cell contact, and suggest that the effect of the CD28 signal indeed consists in prolonging IL-2 production and amplifying T cell responses, rather than in providing a critical co-stimulatory signal at the time of initial TCR triggering.
Introduction
The interaction of CD28 on T cells with the B7 family (B7-1/ anti-CD28 mAb or by CD80 or CD86 co-stimulates T cell proliferation, cytokine production (in particular IL-2 produc-CD80 and B7-2/CD86) molecules on professional antigenpresenting cells (APC) provides a crucial co-stimulatory signal tion) and generation of cytotoxic activity (4-8). CTLA-4 is a second counter-receptor for both CD80 and CD86, and is for T cell activation (1,2). CD80 and CD86 are members of the Ig superfamily, and their expression is restricted to different expressed on activated T cells on which it functions as a negative signal receptor (9-12). A fusion protein, CTLA-4-Ig, types of professional APC (2,3). The CD28 molecule is expressed on the majority of T cells. Ligation of the CD28 by composed of the extracellular domain of CTLA-4 and the Fc part of a human IgG, binds CD80 and CD86 with high obtained from a fusion of SP2/0 murine myeloma cells with splenocytes from a mouse immunized with Sf9 insect cells avidity (9), and has widely been used for blocking B7-CD28 interactions (1,2). It has, for example, been demonstrated expressing the human CD80 molecule (23, 24) . The anti-B7-2 (anti-CD86) mAb IT2.2 was purchased from PharMingen (San that CTLA-4-Ig in vitro blocks alloantigen responses (13), and in vivo reduces specific antibody production, prolongs the Diego, CA). A second mAb to CD86 (clone IG10) was a gift from K. Lorré (Innogenetics, Gent, Belgium). These anti-CD80 survival of organ transplants (14-16) and suppresses several models of autoimmunity (1,2).
and anti-CD86 mAb have been shown to block receptor binding (7, 24, 25) . Clone L243 producing anti-HLA-DR and Surprisingly in view of their important co-stimulatory activity, B7 molecules are either not expressed or have only low clone OKM 1 producing anti-CD11b were obtained from ATCC, and grown in our laboratory. Humanized anti-CD25 (Tac) and expression levels on professional APC. Peripheral blood dendritic cells (DC) are CD80 -and only weakly express anti-CD122 (mikβ-1) mAb were gifts from Dr Hakimi (HofmannLa Roche, Nutley, NJ). A cell line secreting human CTLA-4-CD86, but both molecules are rapidly induced during culture (17) . On the other hand, DC generated in vitro from CD34
Ig fusion protein was a gift from Dr A. Lanzavecchia (Basel Institute of Immunology, Basel, Switzerland). CTLA-4-Ig was precursors express CD80 earlier than CD86 in culture (3). Human peripheral blood monocytes constitutively express used at a final concentration of 10 µg/ml, which was shown in preliminary experiments to completely block co-stimulation low levels of CD86 (7), while CD80 is expressed on monocytes only after activation with IFN-γ or granulocyte macrophage with B7-transfected cells, without having non-specific effects in B7-independent culture systems. Tuberculin was purcolony stimulating factor (18, 19) . Resting human B cells are B7 -and upon activation CD86 appears more rapidly than chased from Statens Serum Institute (Copenhagen, Denmark). Herpes simplex antigens and varicella antigens were from CD80 (20) . An important signal for induction or up-regulation of B7 molecules on all three types of professional APC is the Hoechst (Marburg, Germany), and influenza virus antigen was from Solvay-Duphar (Weest, The Netherlands). Protein interaction of CD40L on activated T cells with CD40 on the APC (21) . The question therefore arises whether the CD28 extracts of Dermatophagoides pteronyssimus (Dp) were prepared from lyophilized mite cultures (kindly provided by signal should be critically delivered at the time of TCR triggering or whether it could also follow TCR triggering. The HAL, Haarlem, The Netherlands). After dialysis with PBS, the resulting Dp extract contained 3.75ϫ10 6 U/ml Dp 1 and latter model would allow time for APC to up-regulate B7. In order to show at what stage of T cell activation the B7-CD28 3.83ϫ10 7 U/ml Dp 2, as compared with the International Reference Preparation for Dp extracts (NIBSC 82/518) (26) . signal exerts its action, we added CTLA-4-Ig or anti-B7 mAb at various time points of the culture to block B7-CD28 IL-2 was purchased from Boehringer Mannheim (Mannheim, Germany) and cyclosporin A (CsA) from Sandoz (Basel, interactions in alloantigen-specific and in soluble antigenspecific T cell responses. Our experimental data indicate that Switzerland). B7 co-stimulation has a functional role in the late stages of Proliferation assay T cell activation, both in naive and in memory T cells.
For allogeneic stimulation, T cells (0.5ϫ10 6 /ml) were mixed with allogeneic monocytes (0.05ϫ10 6 /ml) or with ARC cells Methods (0.025ϫ10 6 /ml). For memory T cell activation, PBMC (1ϫ10 6 / ml) were stimulated with tuberculin (20 U/ml), herpes simplex Cells and cell lines antigens (20 U/ml), varicella virus (100 mU/ml) or influenza Peripheral blood mononuclear cells (PBMC) were isolated virus (1/200 dilution) antigens. All cultures were performed in from heparinized blood of healthy donors by Ficoll-Hypaque 96-well round-bottom culture microplates in 200 µl of complete density centrifugation and resuspended in complete medium: culture medium. For blocking studies, either CTLA-4-Ig or RPMI 1640 (Gibco, Paisley, UK) supplemented with 2 mM anti-CD80 and/or anti-CD86 mAb were added at various time L-glutamine, streptomycin (100 µg/ml), penicillin (100 U/ml) points of the culture. The cells were cultured at 37°C in an and 5% heat-inactivated autologous plasma. Monocytes were atmosphere of 5% CO 2 for 6 days. During the last 8 h of the removed by cold agglutination and the T cells were further culture period, the cells were pulsed with 1 µCi [ 3 H]thymidine purified by treatment with Lympho-Kwik (One Lambda, Los (Amersham International, Amersham, UK) per well. ProliferaAngeles, CA) supplemented with complement-fixing anti-NK tion of T cells was expressed as the mean c.p.m. of quadruplicand anti-monocyte mAb, as reported (22) . Enriched monocyte ate wells. preparations were prepared by rosetting of PBMC with AETCytokine production treated sheep red blood cells, removal of E-rosetting cells on Ficoll-Hypaque density gradients, followed by cold aggrega-T cells (1ϫ10 6 /ml) were mixed with allogeneic monocytes tion of monocytes. ARC cells, an Epstein-Barr virus (EBV)-(0.1ϫ10 6 /ml) or with ARC cells (0.05ϫ10 6 /ml). Stimulation transformed B cell line, was obtained from the ATCC (Rockville, with ARC cells was performed in the presence of CsA (27). MD) (HLA-DR8, alleles: DRB7*0801).
CTLA-4-Ig was added initially or at 24 h of the culture. For antigen-specific memory T cell responses, PBMC (1ϫ10 6 /ml) mAb and other reagents were stimulated with recall antigen in the presence or absence of CTLA-4-Ig initially or at 24 h of the culture. To measure All mAb for functional assays were used as purified antibodies. Anti-CD28 mAb 9.3 against a functional epitope of CD28 was IL-2 production, anti-Tac and mikβ-1 mAb (each at 2 µg/ml) were added to the cultures in order to block IL-2 consumption a gift from Dr C. June (Naval Medical Research Institute, Bethesda, MD). B7-24 mAb is an anti-B7-1 (anti-CD80), (28) . Supernatants were collected after various culture periods. IL-2, IFN-γ and IL-5 were assayed by ELISA using pairs of mAb (anti-IL-2 Screening Line from Genzyme, Cambridge, MA, anti-IFN-γ Screening Line from Medgenix Diagnostics, Fleurus, Belgium and paired anti-IL-5 mAb from PharMingen). Ninety-six-well plastic plates (Nunc-Immuno plate) were coated overnight with anti-cytokine capture mAb. Culture supernatants or standard solutions were added together with the respective biotinylated anti-cytokine detecting mAb. The plates were incubated, washed, and subsequently peroxidase-conjugated streptavidin and tetramethylbenzidine chromogen solution were added. Optical density readings were done at 450 nm on an ELISA reader.
Anergy induction
The protocol to induce alloantigen-specific anergy has previously been published (29) . In brief, T cells (1ϫ10 6 cells) were mixed with ARC cells (0.05ϫ10 6 cells) in 1 ml of complete culture medium on a 24-well culture plate. CsA (400 ng/ml) and anti-CD80 plus anti-CD86 mAb or CTLA-4-Ig were added at the beginning of the culture or 1 day later. After 5-6 days of incubation, the cells were washed, rested for 2 days and re-stimulated by original stimulator cells. The proliferative response and cytokine production upon alloantigen rechallenge were determined as explained above. CTL activity was (29).
(10 µg/ml) was added at various time points to cultures of T cells (0.5ϫ10 6 ml) with allogeneic monocytes (0.05ϫ10 6 ml). Proliferative responses were determined by measuring proliferation almost to the same extent as when added at culture initiation. CTLA-4-Ig still had inhibitory effects when added after 48 h of incubation (P Ͻ 0.03) (see Fig. 1A ). We Table 1 . Inhibition of T cell activation with mAb to CD80/CD86 similarly tested whether memory T cell activation requires B7-in mixed leucocyte cultures a CD28 interaction at an early stage of the activation process. To address this issue, PBMC were stimulated with recall Ig added at various time points. As shown in Fig. 1(B Blocking mAb to B7-1 (CD80) and B7-2 (CD86) have sub- stimulation, similar to anti-HLA-DR. The data of Fig. 2 confirm Fig. 3 . Effects of mAb to CD80 or CD86, added at various time points, on T cell proliferation to several antigens. Anti-CD80 and anti-CD86 mAb (10 µg/ml), alone or in combination, were added at various time points to cultures of PBMC with tuberculin (20 U/ml), herpes simplex antigens (20 U/ml), varicella (100 mU/ml) or influenza (1/200) antigens. Proliferation was determined on day 6. Results are from one experiment.
Fig. 2.
Effect of anti-B7 mAb, added at different time points, on T cell activation induced by allogeneic monocytes (two independent experiments). T cells were cultured at a concentration of 0.5ϫ10 6 cells/ml with 10% allogeneic monocytes. mAb to CD80 and CD86 (2.5 µg/ml) or to CD11b (5 µg/ml) were added at different time points (0, 24, 48, 72 or 144 h). To the control cultures an equal value of medium was added. Proliferation was measured on day 6. that these mAb, similar to CTLA-4-Ig, also inhibit allogeneic T cell activation when added 24 h after culture initiation. In donor A, inhibition even persisted when anti-CD80/CD86 mAb anti-CD80 mAb alone added at different time points had no inhibitory effect while anti-CD86 mAb inhibited the proliferation to several antigens when added either at the start or at day Delayed addition of anti-CD28 mAb 9.3 overcomes T cell 1 of the culture. In some experiments, the addition of CD86-inhibition by CTLA-4-Ig blocking agents could even be delayed up to 72 h with persistence of the inhibitory effect. This can also be seen in
In the next experiments, we studied whether the CD28 signal can be delayed for 24 h after TCR triggering. Purified T cells Fig. 4 which shows an experiment where the effects of CTLA-4 Ig, anti-CD80 and anti-CD86 or anti-CD86 alone were were mixed with allogeneic monocytes and CTLA-4-Ig was added at the beginning. Figure 5 shows that CTLA-4-Ig compared for their inhibitory effect on allergen-induced T cell proliferation. strongly inhibited T cell proliferation and that mAb 9.3 (anti- T cells (0.5ϫ10 6 /ml) were ml) were mixed with 0.1ϫ10 6 allogeneic monocytes (A) or with mixed with allogeneic monocytes (0.05ϫ10 6 /ml) in the absence or 0.05ϫ10 6 ARC (an EBV-transformed B cell line) and CsA (400 ng/ presence of CTLA-4-Ig (10 µg/ml) added at time 0. Anti-CD28 mAb ml) (B). CTLA-4-Ig was added at time 0 or 24 h after initiation of the (10 µg/ml) or IL-2 (20 U/ml) was added after 24 h of the culture. The culture. Anti-Tac (anti-CD25) and mikβ-1 (anti-CD122) (2 µg/ml) were proliferative responses were determined at various time points (Exp. 1) added at the start of the experiment to block IL-2 consumption. The or after 6 days of incubation (Exp. 2).
supernatants were collected at various time points as indicated and IL-2 was measured by ELISA.
CD28) added 1 day later overcame the inhibition. These data are in accordance with the inhibitory effects obtained by delayed addition of CTLA-4-Ig and further suggest that the the beginning and it stopped production of IL-2 when added CD28 signal has a functional role in late stages of T cell 24 h after the start of the culture. activation. As also shown in Fig. 5 , the inhibition of the T cell proliferative response by CTLA-4-Ig was similarly reversed Anergy can be induced by delayed addition of B7-blocking by addition of IL-2 after 24 h. These results suggest that late agents 24 h after initiation of the culture B7 co-stimulation is required for optimal IL-2 production.
Previously, we reported that the combination of anti-B7 mAb
CTLA-4-Ig stops IL-2 production when added 24 h after
and CsA can induce reversible and alloantigen-specific T cell initiation of a mixed lymphocyte reaction anergy against EBV-transformed B cells (29) . If B7-CD28 We therefore investigated the effect of delayed addition of interaction is mainly important in late stages of the T cell CTLA-4-Ig on the production of IL-2 in cultures of T cells activation process, then delayed addition of B7-blocking mixed with allogeneic monocytes or B cells. The supernatants agents together with CsA should still induce anergy. To prove were collected after different culture periods. It should be this, T cells were mixed with ARC in the absence or presence noted that in these cultures, IL-2 consumption was blocked of mAb to CD80 and CD86 or CTLA-4-Ig and CsA, added with anti-IL-2R mAb. As Fig. 6(A) shows, addition of CTLA-4-either at initiation or after 1 day (Fig. 7) . The cells were cultured Ig at the start of the experiment, but also when added 24 h for 6 days, washed and rested for 2 days. Subsequently, a after initiation of the culture, strongly reduced the production secondary stimulation was performed in the absence of of IL-2 as compared to the control cultures. We then performed blocking agents (29) . Both procedures with addition of B7-similar experiments by adding CTLA-4-Ig at the start or at 24 blocking agents and CsA either at initiation or after 1 day h of cultures of T cells mixed with an EBV-transformed B cell were found to have the same efficiency for anergy induction, line (ARC) in the presence of CsA (Fig. 6B) . The rationale of as tested at the level of T cell proliferation, of T cell cytotoxicity, using CsA is that ARC cells are very strong stimulators and and of both T h 1 (IFN-γ) and T h 2 (IL-5) type cytokine production that the effect of CTLA-4-Ig or anti-B7 mAb on ARC-induced (Fig. 7) . Anergy could not be induced by early or delayed IL-2 production could only be observed in the presence of addition of mAb anti-CD80/anti-CD86, CTLA-4-Ig or CsA CsA (27, 29) . Under these circumstances CTLA-4-Ig again almost completely blocked IL-2 production when added at alone (not shown).
by late effects of CD28 signaling, either on mRNA translation or on mRNA stability. Stabilization of mRNA for cytokines has indeed been shown to occur as a result of CD28 triggering (31) and might be the major effect of this co-stimulatory pathway. An alternative explanation is provided by the findings that CD28 triggering is required for Bcl-x L up-regulation and prevention of apoptosis (32) . Further studies on Bcl-x L and on apoptosis after delayed blocking of B7 might resolve these issues. Moreover, both effects are not mutually exclusive and an excess of IL-2 in the absence of CD28 triggering might also prevent apoptosis.
In our experiments, addition of mAb anti-CD80 and anti-CD86 at different time points to cultures of PBMC with recall antigens revealed that a prolonged or late CD86 signal (and not the CD80 signal) is responsible for prolongation of T cell responses. Interestingly, we observed that anti-CD80 mAb had no effect on T cell responses, also not when added after 24 or 48 h. These findings thus do not support the hypothesis that CD80, as it slowly appears on APC, functions to augment late stages of T cell activation (7). As shown in our previous study on this matter (30) , an inhibitory effect of anti-B7-1 mAb could, however, be demonstrated when anti-B7-2 was also of B7-blocking agents and CsA. T cells (1ϫ10 6 /ml) from two different added to the cultures. Thus, B7-2 is the major co-stimulator donors (donor 1, a and b; donor 2, c and d) were mixed with on monocytes, while low levels of B7-1 become relevant only irradiated (3000 rad) ARC (0.05ϫ10 6 /ml) either alone (control), or in the presence of mAb to CD80 and CD86 (10 µg/ml) and CsA (400 when no B7-2 is available. This point in fact supports the ng/ml) (donor 1) or CTLA-4-Ig (10 µg/ml) and CsA (400 ng/ml) (donor conclusion in the present manuscript, because B7-1 was dissociates from CTLA-4 (33), so that it can mainly function to deliver a negative signal for ongoing T cell activation (10-12).
Discussion
Further evidence that prolonged B7-CD28 interaction is required for the late stages of T cell activation comes from our In this study, we investigated the effect of blocking B7-CD28 interaction at different time points of primary (alloantigenfindings on anergy induction. We used the anergy induction protocol as reported by us before (29) . Addition of mAb to specific) or memory (soluble antigen-induced) T cell responses. We demonstrate that addition of B7-blocking CD80 and CD86 or CTLA-4-Ig together with CsA to a primary mixed lymphocyte reaction with ARC as stimulators induces agents at 24 h and in some instances even up to 72 h of culture still significantly inhibited T cell proliferation. Furthermore, we alloantigen-specific anergy. We now report that addition of these blocking agents can be delayed for 24 h after contact demonstrate that delayed addition of anti-CD28 mAb can restore the T cell proliferation in cultures in which B7-CD28 with alloantigen and still induce anergy with a similar efficiency. Anergy induction probably requires partial T cell activation interaction has been blocked at the start of experiment. We interpret these results as a strong indication that B7 co-(34). Since B7-CD28 interaction is not required at the time of TCR triggering, T cells can indeed enter the initial stages of stimulation is not required for the early stage of T cell activation but that it has a role for optimizing T cell responses by activation even in the presence of B7-blocking agents. These partly activated T cells will thus require IL-2 in order to prevent enhancing IL-2 production after the first 24 h of T cell culture. Indeed, CTLA-4-Ig added at 24 h of the culture strongly anergy induction during the ensuing stage of T cell expansion. Lack of IL-2 is indeed a determining factor for anergy inducreduced further IL-2 production, while addition of IL-2 24 h after initiation of the culture in the presence of CTLA-4-Ig tion, as found by Boussiotis et al. (35) . Blocking the B7-CD28 signal even after 24 h inhibits IL-2 production (this report) totally restored T cell proliferation, confirming that lack of IL-2 is responsible for decreased T cell growth. It is interesting to and addition of rIL-2 to the primary mixed lymphocyte reaction prevents anergy induction (29) . Although some IL-2 was note that mRNA for IL-2 can be detected 7 h after stimulation of PBMC with antigens (unpublished observation) and that produced during the first 24 h, this low concentration of IL-2 apparently is unable to prevent anergy induction. thus mRNA for IL-2 is present at time 24 h when CTLA-4-Ig is added. Our finding that initial or delayed addition of CTLA-
The fact that the blockade of the B7-CD28 interaction after TCR triggering and during the further process of T cell 4-Ig almost equally affects IL-2 production as measured between 48 and 72 h could therefore most easily be explained activation still can efficiently inhibit T cell responses may be proliferation (38) . Interestingly, it was also found with CD28 functional T cell responses in vivo (39).
